Development of an HPLC Method Using Chemometric Approaches for the Determination of Latanoprostene Bunod in Pharmaceutical Preparations

Year 2026, Volume: 30 Issue: 1, 126 - 133, 11.01.2026

Sakine Atila Karaca , Büşra Güvercin

https://doi.org/10.12991/jrespharm.1695536

Abstract

Latanoprostene bunod has recently emerged as a promising ocular antihypertensive agent due to its potent ability to lower intraocular pressure and its favorable safety profile observed in clinical trials. In this study, a new, simple, and selective HPLC method was developed for quantifying latanoprostene bunod in pharmaceutical formulations. A Box-Behnken experimental design was employed to optimize the chromatographic parameters, including flow rate, organic solvent, and acid content in the mobile phase. The analysis was performed on an C18 column (4.6 × 50 mm, 3.5 µm), with a mobile phase consisting of water and acetonitrile, both containing 0.01% formic acid (45:55, v/v). Chromatographic conditions were set at a flow rate of 0.6 mL/min, a column temperature of 40 °C, and detection at 260 nm. Method validation, following the ICH Q2(R1) guideline, demonstrated excellent linearity over the concentration range of 0.50–20.00 µg/mL, with LOD and LOQ values of 0.052 µg/mL and 0.157 µg/mL, respectively. Precision and accuracy were confirmed with recovery rates between 100-102% and RSD values below 3%, respectively. The validated method was then successfully applied to the analysis of latanoprostene bunod in a commercially available ophthalmic formulation, confirming its suitability for routine quality control use.

Keywords

chromatography , pharmaceutical analysis , latanoprostene bunod , experimental design

Project Number

This study was supported by the Scientific and Technological Research Council of Türkiye (TÜBİTAK), through the 2209-A Research Project Support Program for Undergraduate Students.

References

• [1] Garcia G, Ngai P, Mosaed S, Lin K. Critical evaluation of latanoprostene bunod in the treatment of glaucoma. Clinical Ophthalmology 2016;10:2035–2050. https://doi.org/10.2147/OPTH.S103985.
• [2] Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother 2017;18:433–444. https://doi.org/10.1080/14656566.2017.1293654.
• [3] Harasymowycz P, Royer C, Cui AX, Barbeau M, Jobin-Gervais K, Mathurin K, Lachaine J, Beauchemin C. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. Br J Ophthalmol 2022;106:640–647. https://doi.org/10.1136/bjophthalmol-2020-317262.
• [4] Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye 2020;34:72–88. https://doi.org/10.1038/s41433-019-0671-0.
• [5] Wang Y, Liao Y, Nie X. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma. Clinics 2020;75:e1874. https://doi.org/10.6061/clinics/2020/e1874.
• [6] Walash M, El-Shaheny R. Fast separation and quantification of three anti-glaucoma drugs by high-performance liquid chromatography UV detection. J Food Drug Anal 2016;24:441–449. https://doi.org/10.1016/j.jfda.2015.11.006.
• [7] Patel P, Patel P, Giram P. Bioanalytical method development and validation for latanoprost quantification in pharmaceutical opthalmic microemulsion formulation by RP-HPLC. J Anal Bioanal Tech 2015;6:1–5.
• [8] Ankit A, Sunil T, Kashyap N. Method development and its validation for quantitative simultaneous determination of latanoprost, timolol and benzalkonium chloride in ophthalmic solution by RP-HPLC. J Drug Deliv Ther. 2013;3:26–30.
• [9] Stojanović J, Krmar J, Protić A, Svrkota B, Đajić N, Otašević B. Experimental design in HPLC separation of pharmaceuticals. Arh Farm (Belgr) 2021;71:279–301. https://doi.org/10.5937/arhfarm71-32480.
• [10] Vera Candioti L, De Zan MM, Cámara MS, Goicoechea HC. Experimental design and multiple response optimization. Using the desirability function in analytical methods development. Talanta 2014;124:123–138. https://doi.org/10.1016/j.talanta.2014.01.034.
• [11] ICH Q2(R1). Validation of Analytical Procedures: Text and Methodology. 2005.
• [12] Hibbert DB. Experimental design in chromatography: A tutorial review. J Chromatogr B 2012;910:2–13. https://doi.org/10.1016/j.jchromb.2012.01.020.
• [13] Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. J Chromatogr A 2003;987:57–66. https://doi.org/10.1016/S0021-9673(02)01536-4.